Medincell Launches a Private Placement for International Institutional Investors

Regulatory News:

THIS PRESS RELEASE IS NOT BEING MADE IN AND COPIES OF IT MAY NOT BE DISTRIBUTED OR SENT, DIRECTLY OR INDIRECTLY, INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA

Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments (the “Company”), today announced the launch of a private placement of approximately 6% of the Company’s share capital, targeted at international institutional investors through an accelerated book‑building process.

The net proceeds from the private placement, together with the Company’s existing cash resources, are expected to support and accelerate the execution of Medincell’s growth strategy.

In particular, the Company intends to allocate the net proceeds to:

• Expand partnering opportunities by generating high value data through the initiation of additional programs,

• Maximize the value of future partnerships by optimizing economics and prioritizing downstream royalty participation,

• Strengthen the proprietary LAI technology platform through targeted innovation, including the advancement of next‑generation LAI technologies that may broaden the scope, differentiation and applications of the platform.

The net proceeds may also be used for general corporate purposes, including working capital and operating expenses, and to strengthen the Company's balance sheet to support future strategic initiatives and enhance financial flexibility.

Christophe Douat, CEO of Medincell, said: “Medincell is undergoing a transformation from a technology platform company into a royalty‑driven company focused on long‑term, scalable value creation. Innovation remains at the core of our strategy as we strengthen our position in the growing field of long‑acting injectables, starting in psychiatry - where the value of LAIs is clearly established - and expanding into other therapeutic areas. Our approach combines scientific innovation, disciplined execution, and a long‑term focus on downstream value through strong partnerships.”

Medincell’s portfolio as of February 20, 2026

UZEDY, the first product developed using Medincell’s proprietary BEPO technology and commercialized by Teva Pharmaceuticals, generated net sales of $191 million in the United States in 2025, its second full year of commercialization, in line with expectations. Teva’s initial net sales outlook for UZEDY in 2026 is in the range of $250 million to $280 million.